{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464206801
| IUPAC_name = 7-chloro-5-phenyl-1-prop-2-yn-1-yl-1,3-dihydro-2''H''-1,4-benzodiazepin-2-one
| image = Pinazepam.svg
| width = 175
| image2 = Pinazepam3d.png
| width2 = 160

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|pinazepam}}
| pregnancy_category =
| legal_CA = Schedule IV
| legal_DE = Anlage III
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism = [[Liver|Hepatic]]
| elimination_half-life =
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 52463-83-9
| ATC_prefix = N05
| ATC_suffix = BA14
| PubChem = 40391
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = ?
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 36899
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5286RBZ882
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07314
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1213352

<!--Chemical data-->
| C=18 | H=13 | Cl=1 | N=2 | O=1 
| molecular_weight = 308.8
| smiles = Clc3cc\1c(N(C(=O)C/N=C/1c2ccccc2)CC#C)cc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H13ClN2O/c1-2-10-21-16-9-8-14(19)11-15(16)18(20-12-17(21)22)13-6-4-3-5-7-13/h1,3-9,11H,10,12H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MFZOSKPPVCIFMT-UHFFFAOYSA-N
| synonyms = <small>9-chloro-6-phenyl-2-prop-2-ynyl-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one</small>
}}

'''Pinazepam''' (marketed under the brand name '''Domar''' and '''Duna''') is a drug that is a [[benzodiazepine]].<ref>{{cite journal |pmid=3146986 |date=Sep 1988 |last1=Schütz |first1=H |last2=Holland |last3=Kazemian-Erdmann |last4=Schölermann |title=Screening of the new benzodiazepine derivative, pinazepan, and its major metabolites |volume=38 |issue=9 |pages=1372–5 |issn=0004-4172 |journal=Arzneimittel-Forschung |first2=EM |first3=F |first4=K }}</ref> It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.

Pinazepam and its metabolite [[Nordazepam|''N''-desmethyldiazepam]] are transferred to the developing fetus ''in utero'', but the plasma drug level in the mother is usually significantly higher than in the fetus.<ref>{{cite journal |pmid=6150857 |year=1984 |last1=Pacifici |first1=GM |last2=Cuoci |last3=Guarneri |last4=Fornaro |last5=Arcidiacono |last6=Cappelli |last7=Moggi |last8=Placidi |title=Placental transfer of pinazepam and its metabolite N-desmethyldiazepam in women at term |volume=27 |issue=3 |pages=307–10 |issn=0031-6970 |journal=European journal of clinical pharmacology |doi=10.1007/BF00542165 |first2=L |first3=M |first4=P |first5=G |first6=N |first7=G |first8=GF }}</ref>

Pinazepam differs from other benzodiazepines in that it has a [[propargyl|propargyl group]] at the ''N''-1 position of the benzodiazepine structure. It is less toxic than diazepam and in animal studies it appears to produce anxiolytic and anti-agitation properties with limited [[hypnotic]] and motor coordination impairing properties. Pinazepam is rapidly absorbed after oral administration. The main active metabolites of pinazepam are depropargylpinazepam (''N''-desmethyldiazepam, [[nordazepam]]) and [[oxazepam]]. In humans pinazepam acts as a pure anxiolytic agent in that it does not possess to any significant degree the other pharmacological characteristics of benzodiazepines. Its lack of intellectual, motor and hypnotic impairing effects makes it more appropriate than other benzodiazepines for day time use.<ref>{{cite journal |pmid=6147192 |year=1984 |last1=Janbroers |first1=JM |title=Pinazepam: review of pharmacological properties and therapeutic efficacy |volume=6 |issue=4 |pages=434–50 |issn=0149-2918 |journal=Clinical therapeutics |url= |format= }}</ref><ref>{{cite journal |pmid=6147314 |year=1983 |last1=Pacifici |first1=GM |last2=Placidi |last3=Fornaro |last4=Gomeni |title=Pharmacokinetics of pinazepam in healthy volunteers |volume=3 |issue=5 |pages=331–7 |issn=0251-1649 |journal=International journal of clinical pharmacology research |first2=GF |first3=P |first4=R }}</ref><ref>{{cite journal |pmid=6809477 |year=1982 |last1=Pacifici |first1=GM |last2=Placidi |last3=Fornaro |last4=Gomeni |title=Pinazepam: a precursor of N-desmethyldiazepam |volume=22 |issue=3 |pages=225–8 |issn=0031-6970 |journal=European journal of clinical pharmacology |doi=10.1007/BF00545219 |first2=GF |first3=P |first4=R }}</ref> The elimination half-life is longer in the elderly.<ref>{{cite journal |pmid=6802645 |date=Jan 1982 |last1=Pacifici |first1=GM |last2=Cuoci |last3=Placidi |last4=Fornaro |last5=Gomeni |title=Elimination kinetics of desmethyldiazepam in two young and two elderly subjects |volume=7 |issue=1 |pages=69–72 |issn=0398-7639 |journal=European journal of drug metabolism and pharmacokinetics |url= |format= |first2=L |first3=GF |first4=P |first5=R |doi=10.1007/bf03189546}}</ref>

==See also==
*[[Benzodiazepine]]

==References==
{{reflist}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim679.htm Inchem - Pinazepam]

{{Benzodiazepines}}
{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Alkynes]]
[[Category:Benzodiazepines]]
[[Category:Chloroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Lactams]]

{{sedative-stub}}